Background Volasertib, a potent and selective polo-like kinase inhibitor, has shown to
increase response rates and improve survival with a clinically manageable safety profile …

Abstract Abstract 82 Introduction: Plerixafor is thought to enhance chemotherapy mediated
myeloid leukemia cell death by promoting mobilization from the protective bone marrow …

Intoplicine (RP 60475) was selected for a phase I evaluation because it inhibits
topoisomerase I and II, and has exhibited antitumor activity against a variety of preclinical …

Abstract Abstract 3316 Background: Patients with refractory or relapsed AML have a poor
prognosis and new treatments are needed for this patient population. While younger AML …

Background Clofarabine, a second-generation nucleoside analogue, was studied in
combination with etoposide and mitoxantrone in acute leukemia. Patients and Methods In …

Activation of phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) signaling plays a role in cell proliferation, survival, and drug resistance in solid …

Objective To assess complete remission (CR), the overall survival (OS), event-free survival
(EFS) and adverse events of newly diagnosed acute promyelocytic leukemia (APL) with …

Abstract Abstract 1549 Background: The prognosis of patients (pts) with relapsed or
refractory (rel/ref) AML who are considered unlikely to benefit from or tolerate intensive …

Volasertib is a potent inhibitor of Polo-like kinase (PLK) 1 and to lesser extent also PLK2 and
PLK3. PLKs are key regulators of the cell cycle and volasertib blocks cells in G2–M phase of …

The acute myeloid leukemias (AML) are often fatal disorders with a range of clinical,
morphologic, cytogenetic, and molecular features and a consequent need for a diverse array …